Gene Symbol: RANKL
Description: TNF superfamily member 11
Alias: CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2, sOdf, tumor necrosis factor ligand superfamily member 11, TNF-related activation-induced cytokine, osteoclast differentiation factor, osteoprotegerin ligand, receptor activator of nuclear factor kappa B ligand, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand 6B, tumor necrosis factor superfamily member 11
Species: human
Products:     RANKL

Top Publications

  1. Canon J, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik P, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008;25:119-29 pubmed
    ..Receptor activator of NF-kappaB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival, and is blocked by a soluble decoy ..
  2. Walsh N, Alexander K, Manning C, Karmakar S, Karmakar S, Wang J, et al. Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL. Genes Immun. 2013;14:336-45 pubmed publisher
    Receptor activator of nuclear factor-kappaB-ligand (RANKL), encoded by the gene TNFSF11, is required for osteoclastogenesis, and its expression is upregulated in pathologic bone loss...
  3. Jones D, Nakashima T, Sanchez O, Kozieradzki I, Komarova S, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-6 pubmed
    ..Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells ..
  4. Odero Marah V, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18:858-70 pubmed publisher
    ..markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-kappaB Ligand (RANKL)...
  5. Dong S, Liu X, Chen Y, Guo Y, Wang L, Zhao J, et al. Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. Calcif Tissue Int. 2009;85:104-12 pubmed publisher
    ..activator of the nuclear factor-kappaB ligand/receptor activator of the nuclear factor-kappaB/osteoprotegerin (RANKL/RANK/OPG) pathway in the regulation of bone remodeling, we tested the associations between RANKL/RANK/OPG ..
  6. Roshandel D, Holliday K, Pye S, Boonen S, Borghs H, Vanderschueren D, et al. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. J Bone Miner Res. 2010;25:1830-8 pubmed publisher
    The aim of this study was to determine if single-nucleotide polymorphisms (SNPs) in RANKL, RANK, and OPG influence bone turnover and bone mineral density (BMD) in men. Pairwise tag SNPs (r(2) > or = 0...
  7. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, et al. Receptor activator for nuclear factor ? B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol. 2012;65:36-40 pubmed publisher
    It was recently reported that receptor activator for nuclear factor ? B ligand (RANKL)/receptor activator for nuclear factor ? B (RANK) pathway is critical for RANK-expressing cancer cells to home to bone and associates with disease ..
  8. Bhatia P, Sanders M, Hansen M. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res. 2005;11:162-5 pubmed
    During normal bone remodeling, the receptor activator of nuclear factor-kappaB (RANK) interacts with its ligand RANKL, which is present on pre-osteoclasts, resulting in bone resorption and initiation of new bone formation...
  9. Paternoster L, Lorentzon M, Lehtimaki T, Eriksson J, Kahonen M, Raitakari O, et al. Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet. 2013;9:e1003247 pubmed publisher
    ..by replication (n?=?1,052) identified genetic variants in four separate loci reaching genome-wide significance (RANKL, rs1021188, p?=?3.6×10?¹?; LOC285735, rs271170, p?=?2.7×10?¹²; OPG, rs7839059, p?=?1...

More Information


  1. Tunyogi Csapo M, Kis Toth K, Radacs M, Farkas B, Jacobs J, Finnegan A, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum. 2008;58:2397-408 pubmed publisher
    ..whether proinflammatory cytokine treatment or the complete absence of select cytokines modulates the expression of RANKL and osteoprotegerin (OPG) in synovial fibroblasts...
  2. Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang S, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS ONE. 2013;8:e58361 pubmed publisher
    ..The RANKL/RANK/OPG system, which plays a pivotal role in bone remodeling by regulating osteoclast formation and activity, is ..
  3. Kim S, Yamazaki M, Zella L, Meyer M, Fretz J, Shevde N, et al. Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2007;103:430-4 pubmed
    One of the primary regulators of receptor activator of NF-kappaB ligand (RANKL) is 1,25-dihydoxyvitamin D(3) (1,25(OH)(2)D(3))...
  4. Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, et al. Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int. 2008;28:987-93 pubmed publisher
    ..T cells have been implicated as a source of receptor activator of NFkappaB ligand (RANKL) in inflammatory bone diseases...
  5. McGonigle J, Giachelli C, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12:35-46 pubmed publisher
    ..In this study, we assessed the role of OPG and its ligands, receptor activator of nuclear factor-kappaB ligand (RANKL) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL), in microvessel formation using the rat ..
  6. Sobacchi C, Frattini A, Guerrini M, Abinun M, Pangrazio A, Susani L, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39:960-2 pubmed
    ..Here we report mutations in the gene encoding RANKL (receptor activator of nuclear factor-KB ligand) in six individuals with autosomal recessive osteopetrosis whose ..
  7. Yuvaraj S, Griffin A, Sundaram K, Kirkwood K, Norris J, Reddy S. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res. 2009;7:1399-407 pubmed publisher
    ..Here in, we show that recombinant hCXCL13 treatment of OSCC cells stimulates (5-fold) RANK ligand (RANKL), a critical bone resorbing osteoclastogenic factor expression...
  8. Lynch C, Hikosaka A, Acuff H, Martin M, Kawai N, Singh R, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485-96 pubmed
    ..MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing RANKL to a soluble form that promoted osteoclast activation...
  9. Duncan E, Danoy P, Kemp J, Leo P, McCloskey E, Nicholson G, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 2011;7:e1001372 pubmed publisher
    ..In addition to identifying further genes associated with BMD, this study confirms the efficiency of extreme-truncate selection designs for quantitative trait association studies. ..
  10. Gonzalez Suarez E, Jacob A, Jones J, Miller R, Roudier Meyer M, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103-7 pubmed publisher
    RANK ligand (RANKL), a TNF-related molecule, is essential for osteoclast formation, function and survival through interaction with its receptor RANK...
  11. Zheng H, Tobias J, Duncan E, Evans D, Eriksson J, Paternoster L, et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet. 2012;8:e1002745 pubmed publisher
    ..Natural variation in humans and targeted disruption in mice demonstrate that WNT16 is an important determinant of CBT, BMD, bone strength, and risk of fracture. ..
  12. Hsu C, Lin T, Kuo C, Tsai C, Lin M, Hsu H, et al. Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration. J Cell Biochem. 2010;111:138-47 pubmed publisher
    ..Receptor activator of nuclear factor-kappaB ligand (RANKL) and its receptor, RANK, play a key roles in osteoclastogenesis and tumor metastasis...
  13. Paternoster L, Ohlsson C, Sayers A, Vandenput L, Lorentzon M, Evans D, et al. OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and gothenburg osteoporosis and obesity determinants cohorts. J Clin Endocrinol Metab. 2010;95:3940-8 pubmed publisher
    ..The association of genes from the RANK/RANKL/OPG pathway and BMDC provides new insight into how this system might affect the skeleton, confirming it to be ..
  14. Chen L, Kuo C, Lai T, Lin Y, Su C, Hsu H, et al. RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem. 2011;112:933-41 pubmed publisher
    ..Receptor activator of nuclear factor-?B ligand (RANKL) and its receptor, RANK, play a key role in osteoclastogenesis and tumor metastasis...
  15. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, et al. Central control of fever and female body temperature by RANKL/RANK. Nature. 2009;462:505-9 pubmed publisher
    Receptor-activator of NF-kappaB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE and ODF) and its tumour necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodelling, lymph node organogenesis and formation of ..
  16. Semb A, Ueland T, Aukrust P, Wareham N, Luben R, Gullestad L, et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009;29:975-80 pubmed publisher
    ..association between serum levels of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) and future coronary artery disease (CAD) in apparently healthy individuals...
  17. Hikita A, Kadono Y, Chikuda H, Fukuda A, Wakeyama H, Yasuda H, et al. Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem. 2005;280:41700-6 pubmed
    The receptor activator of NF-kappaB ligand (RANKL), a critical regulator of osteoclastogenesis, is synthesized as a membrane-anchored protein and cleaved into a soluble form by ectodomain shedding...
  18. Yamada T, Tsuda M, Takahashi T, Totsuka Y, Shindoh M, Ohba Y. RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression. Am J Pathol. 2011;178:2845-56 pubmed publisher
    ..Here, we identify receptor activator of nuclear factor ?B ligand (RANKL) as a microenvironment-specific factor essential for tumorigenesis in vivo, using head and neck squamous cell ..
  19. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng J, Hoffman R, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548-53 pubmed publisher
    ..upregulation of two tumour-necrosis-factor family members: receptor activator of nuclear factor-?B (RANK) ligand (RANKL) and lymphotoxin. But the source of RANKL and its role in metastasis have not been established...
  20. Ng P, Tsui S, Lau C, Wong C, Wong W, Huang L, et al. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem. 2010;110:438-46 pubmed publisher
    ..Expression of the receptor activator of nuclear factor kappa B ligand (RANKL) in the stromal cells stimulates the monocytes to form giant multi-nucleated ..
  21. Hu P, Chung L, Berel D, Frierson H, Yang H, Liu C, et al. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS ONE. 2013;8:e73081 pubmed publisher
    We reported (PLoS One 6 (12):e28670, 2011) that the activation of c-Met signaling in RANKL-overexpressing bone metastatic LNCaP cell and xenograft models increased expression of RANK, RANKL, c-Met, and phosphorylated c-Met, and mediated ..
  22. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116:385-91 pubmed
    Overexpression of receptor activator of nuclear factor-kappaB ligand (RANKL) is a prominent feature of vulnerable atherosclerotic lesions prone to rupture and was thought to contribute to the transition from a stable to an unstable ..
  23. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum. 2005;52:2307-12 pubmed
    The RANK/RANKL pathway is critical in bone destruction in conditions such as rheumatoid arthritis (RA)...
  24. Olesen M, Skov V, Mechta M, Mumm B, Rasmussen L. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol. 2012;362:149-56 pubmed publisher
    The aim of this study was to examine the effects of the OPG-RANKL-TRAIL system on proliferation, regulation of calcification-associated genes and calcification of human vascular smooth muscle cells (HVSMCs)...
  25. Hsu Y, Niu T, Terwedow H, Xu X, Feng Y, Li Z, et al. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet. 2006;118:568-77 pubmed
    In order to assess the contribution of polymorphisms in the RANKL (TNFSF11), RANK (TNFRSF11A) and OPG (TNFRSF11B) genes to variations in bone mineral density (BMD), a population-based cohort with 1,120 extreme low hip BMD cases or ..
  26. Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, et al. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest. 2008;31:163-8 pubmed
    ..The increase in circulating free sRANKL may reflect directly or indirectly the conditions coexistent with bone loss in post-menopausal women. ..
  27. Styrkarsdottir U, Halldorsson B, Gretarsdottir S, Gudbjartsson D, Walters G, Ingvarsson T, et al. New sequence variants associated with bone mineral density. Nat Genet. 2009;41:15-7 pubmed publisher
    ..Furthermore, nonsynonymous SNPs in the C17orf53, LRP4, ADAM19 and IBSP genes were suggestively associated with bone density. ..
  28. Collin Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95:1046-57 pubmed
    ..One emerging area in vascular biology involves the RANKL/RANK/OPG system, molecules of the tumor necrosis factor-related family recently discovered to be critical ..
  29. Boyce B, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9 Suppl 1:S1 pubmed
    The discovery of the receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies how both serendipity and a logic-based approach can identify ..
  30. Lu Y, Liu P, Recker R, Deng H, Dvornyk V. TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause. 2010;17:1048-54 pubmed publisher
    ..We tested two genes, TNFRSF11A (RANK) and TNFSF11 (RANKL), for their association with age at menarche (AM) and age at natural menopause (ANM)...
  31. Paternoster L, Lorentzon M, Vandenput L, Karlsson M, Ljunggren O, Kindmark A, et al. Genome-wide association meta-analysis of cortical bone mineral density unravels allelic heterogeneity at the RANKL locus and potential pleiotropic effects on bone. PLoS Genet. 2010;6:e1001217 pubmed publisher
    ..The rs1021188 SNP (near RANKL) was associated with BMD(C) in all cohorts (overall p?=?2×10(-14), n?=?5739)...
  32. Goranova Marinova V, Goranov S, Pavlov P, Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica. 2007;92:1000-1 pubmed
    Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly-diagnosed patients with multiple myeloma (MM)...
  33. Kim J, Kim J, Kim J, Ku S, Jee B, Suh C, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause. 2007;14:913-8 pubmed
    ..association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL (sRANKL) levels, and bone mineral density (BMD) in Korean ..
  34. Styrkarsdottir U, Halldorsson B, Gretarsdottir S, Gudbjartsson D, Walters G, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355-65 pubmed publisher
    ..be important to the biologic characteristics of bone: the receptor activator of nuclear factor-kappaB ligand gene (RANKL) (chromosomal location, 13q14), the osteoprotegerin gene (OPG) (8q24), and the estrogen receptor 1 gene (ESR1) (..
  35. Sasaki A, Ishikawa K, Haraguchi N, Inoue H, Ishio T, Shibata K, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis. Ann Surg Oncol. 2007;14:1191-9 pubmed
    Although receptor activator of nuclear factor-kappaB ligand (RANKL) seems to be involved in the development of bone metastases in several malignant tumors, its role in hepatocellular carcinoma (HCC) has not been investigated...
  36. O Brien C. Control of RANKL gene expression. Bone. 2010;46:911-9 pubmed publisher
    ..Only one of these cytokines, receptor activator of NFkappaB ligand (RANKL), is absolutely essential for osteoclast formation throughout life and is thus expressed by all cell types that ..
  37. Assmann G, Koenig J, Pfreundschuh M, Epplen J, Kekow J, Roemer K, et al. Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study. J Rheumatol. 2010;37:900-4 pubmed publisher
    ..Genetic variations in the genes coding for RANK, RANK ligand (RANKL), and OPG are thought to play roles in the susceptibility to RA...
  38. Mellis D, Itzstein C, Helfrich M, Crockett J. The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol. 2011;211:131-43 pubmed publisher
  39. Lee J, Jung J, Kim D, Lim J, Kim M, Kong C, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer. 2011;56:738-43 pubmed publisher
    The receptor activator of nuclear factor ?B ligand (RANKL/TNFSF11) is expressed in metastatic bone cancer cells and has been suggested to play a key role in cell migration and metastatic behavior...
  40. Owen S, Ye L, Sanders A, Mason M, Jiang W. Expression profile of receptor activator of nuclear-?B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33:199-206 pubmed
    ..Receptor activator of nuclear-?B (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are a group of important regulators for osteoclast differentiation and activation...
  41. Chu G, Zhau H, Wang R, Rogatko A, Feng X, Zayzafoon M, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 2014;21:311-26 pubmed publisher
    ..Here, we report that receptor activator of NF-κB ligand (RANKL) expressed by PCa cells consistently induced colonization or metastasis to bone in animal models...
  42. Tseng W, Graham L, Geng Y, Reddy A, Lu J, Effros R, et al. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem. 2010;285:29925-31 pubmed publisher
    ..osteoblast-production of osteoclast regulating cytokines, including receptor-activator of nuclear ?B ligand (RANKL) and interleukins...
  43. Mackiewicz Z, Salo J, Konttinen Y, Kaigle Holm A, Indahl A, Pajarinen J, et al. Receptor activator of nuclear factor kappa B ligand in an experimental intervertebral disc degeneration. Clin Exp Rheumatol. 2009;27:299-306 pubmed
    This study was designed to clarify the role of the receptor activator of nuclear factor kappa B ligand (RANKL) in the process of discus degeneration and spondylarthrosis...
  44. Vega D, Maalouf N, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92:4514-21 pubmed
    Receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling and disorders of mineral metabolism...
  45. Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem. 2006;281:36846-55 pubmed
    Receptor activator of NF-kappaB ligand (RANKL) is a transmembrane glycoprotein that has an essential role in the development of osteoclasts...
  46. Schneeweis L, Willard D, Milla M. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem. 2005;280:41155-64 pubmed
    ..Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction. ..
  47. Takacs I, Lazary A, Kósa J, Kiss J, Balla B, Nagy Z, et al. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression. Eur J Endocrinol. 2010;162:423-31 pubmed publisher
    Receptor activator of nuclear factor-kappaB ligand/osteoprotegerin (RANKL/OPG) signaling system plays a crucial role in the regulation of bone resorption...
  48. Mabilleau G, Petrova N, Edmonds M, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51:1035-40 pubmed publisher
    ..and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG)...
  49. Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, et al. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol. 2005;35:3353-63 pubmed
    ..The concentration of soluble receptor activator of NF-kappaB ligand (RANKL) and IFN-gamma, and the amount of membrane type RANKL expressed on T cells, were measured by ELISA...
  50. Wong B, Besser D, Kim N, Arron J, Vologodskaia M, Hanafusa H, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999;4:1041-9 pubmed
    b>TRANCE, a TNF family member, and its receptor, TRANCE-R, are critical regulators of dendritic cell and osteoclast function...
  51. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun. 2000;269:532-6 pubmed
    A novel cDNA encoding a secreted form of osteoclast differentiation factor/tumor necrosis factor-related activation-induced cytokine (sODF/TRANCE, GenBank Accession No...
  52. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-602 pubmed
    ..We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their ..
  53. Schoppet M, Al Fakhri N, Franke F, Katz N, Barth P, Maisch B, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004;89:4104-12 pubmed
  54. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100:4615-21 pubmed
    ..the cross-talk between the critical osteoclastogenetic factor, receptor activator of nuclear factor-kappaB ligand (RANKL), and interferon gamma (IFN-gamma) that strongly suppresses osteoclastogenesis...
  55. Atkins G, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res. 2003;18:1088-98 pubmed
    ..Osteoblast differentiation markers were examined in relation to RANKL expression. RANKL expression was induced preferentially in immature cells...
  56. Cremer I, Dieu Nosjean M, Maréchal S, Dezutter Dambuyant C, Goddard S, Adams D, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood. 2002;100:3646-55 pubmed
    ..We have identified int-DCs that express both TRANCE (tumor necrosis factor-related activation-induced cytokine) and RANK (receptor activator of NF-kappaB) and have ..